A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Cyclophosphamide|DRUG: Placebo|DRUG: Doxorubicin|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Veliparib|DRUG: Placebo
Sponsor: AbbVie
Collaborators: German Breast Group|NSABP Foundation Inc|Grupo Español de Investigación del Cáncer de Mama|US Oncology Research